TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Testosterone Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants seeking hearing healthcare
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cylinder test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of grade 2-4 complications
Endpoint domain: Adverse events/effects
Primary endpoint: Psychological assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurocognitive measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Weekday moderate-vigorous physical activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Thickness of gluteal muscle and fat tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax (Maximum Observed Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (Time of Maximum Observed Plasma Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 (Apparent Terminal Elimination Half-life)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical characteristics of idiopathic systemic vasculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMRO2 determination during brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reliability and sensitivity of functional imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measurement of metabolite and neurotransmitter concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of long-term Phenoptin treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Sexual Bother
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tau imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency, duration and severity of drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum drug concentration at steady-state (Cmax-ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confirmed partial and complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in C3 Deposit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of oligosaccharides in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 3 Minutes Stair Climb Test (3MSCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival probabilities
Endpoint domain: Mortality/survival
Primary endpoint: Change in daytime LH pulse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients achieving 75% reduction in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancouver scar scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Retinal shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Positive Anti-Drug Antibodies (ADA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of arousals/awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of conjunctival vascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Total Toxicity Burden (TTB)
Endpoint domain: Adverse events/effects
Primary endpoint: objective responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in ¹⁸F-AV-1451 PET Standard Uptake Value Ratio (SUVr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory dynamic compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory minute volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressure carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Partial pressure oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hypoxemic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative incidence rate of hepatitis B viral reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: 3-month postoperative ankle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary cortisol levels in preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number and Severity of Falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic balance and mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual-task gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion (ROM) of forearm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Manic Syndrome Scale (MSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Behavior and Ideation Scale (BIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procurement and analysis of data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to first occurrence of urgent coronary revascularization for myocardial ischemia
Endpoint domain: Mortality/survival
Primary endpoint: Time to first occurrence of stroke (fatal/non-fatal)
Endpoint domain: Mortality/survival
Primary endpoint: Time to subsequent Major Adverse Cardiovascular Events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first occurrence of heart failure requiring hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Various inflammation-related cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Foot health status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Count of Participants With Blisters
Endpoint domain: Adverse events/effects
Primary endpoint: glomerular filtration rate (mGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relief of the rest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of ulcerations or reduction of ulcer area in the target limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ocular alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieved Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First occurrence of a plantar ulcer or pre-ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability as measured by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Gingival indices using Plaque Index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival indices using Periodontal Screening Index (PSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival indices using Sulcus Bleeding Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OCT findings (stented lesions, native vessels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First 3-day Cumulative ICU Traumatic Brain Injury Guideline Adherence Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neuropsychiatric Inventory (NPI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommended Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean procedural cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of BP measurements reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients submitting 1 or more BP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time required for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acceptable fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Basic Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent Change in BMI From Baseline to 14 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Body Fat Change at 14 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with chronic pain that impairs daily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients with pain related impairment of sexual function
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of patients with pain that impairs daily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of quetiapine in treating acute mania and depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Door-to-reperfusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma NEFA appearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac and hepatic uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WAT spillover NEFA appearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fatigue Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: In-hospital unexpected death
Endpoint domain: Mortality/survival
Primary endpoint: Unplanned ICU admission
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac arrest
Endpoint domain: Adverse events/effects
Primary endpoint: BMPR2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Performed Regular Self-Skin Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Correct Answers on Melanoma Perception Pre-intervention and 2 Months Post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of recruiting target population
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Administration of study therapies according to pre-defined protocols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Following patients for clinical endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral vasospasm incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preoperative anxiety difference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of select markers of inflammation and destruction in the synovium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and nature of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: boceprevir concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to achieve and maintain ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of metformin
Endpoint domain: Adverse events/effects
Primary endpoint: Anemia control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wong-Baker Faces Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-Form STAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Shigellosis
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Meaningful Improvement in Patient-reported Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of participants progressing to high/very high risk MDS or AML
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants progressing to high/very high risk MDS or AML
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants developing other malignancies/pre-malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants developing other malignancies/pre-malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Level of social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: treatment related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: safety of subcutaneous administration
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in knowledge surrounding SRA policy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stability of anxiety surrounding SRA policy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in trust surrounding SRA policy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MCV drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional Gait Assessment (FGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision of Femoral or Tibial Cone Augment for aseptic loosening
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain Quality Assessment Scale (PQAS) unpleasantness score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Impact of Events scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opioid Use at 3 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opioid Use at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients with major adverse events (MAE rates)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mitral regurgitation severity (scale of 0-4+) by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin pH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin moisture level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Early diagnosis of acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gross Motor Function Measure-66
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Observation Coding System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Patients With a Positive Autoantibody ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-blood-glucose-monitoring results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Induction of BTIC Lysate-specific T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proliferative capacity of keratinocytes and fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BPI Average Pain From Baseline to Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gaseous interchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of mutations causing aberrant signaling pathway function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability: AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Best overall response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Symptom Assessment in Dry Eye (SANDE) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Composite Corneal Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodic Memory Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in IL-23R levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV positive seroconversion rate
Endpoint domain: Mortality/survival
Primary endpoint: Additional cost of the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inflammatory markers (TNF-alpha and IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Moderate or Greater Paravalvular Leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in average power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observance of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adaptation of procedural practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation of provider staffing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adaptation of techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation of ambulatory operations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: TCD Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy in Patient Physician Interactions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Active Patient Participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of extra-pedicular or extra bone trips
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Mean Sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response times to solve an informatics task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achievement of desired activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Health care utilization defined by healthcare contact days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intraoperative blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Maximal Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of favourable cervix (Bishop score of 8 or more)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes